“The topline results from Ascletis’ Phase 3 open-label acne trial in China build additional confidence in the clinical potential of FASN inhibition in acne,” said David Happel, Chief Executive Officer ...

We all want a flawless, bright-eyed, smooth, clear face. But whether it’s spots, dry skin, flushed cheeks or cracked lips, we ...

Almirall, S.A. (ALM) a global pharmaceutical company dedicated to medical dermatology announced today that China’s National Medical Products Administration (NMPA) has approved Seysara® (sarecycline ...

Almirall’s Seysara receives China NMPA approval for treatment of moderate-to-severe acne: Barcelona, Spain Saturday, January 31, 2026, 11:00 Hrs [IST] Almirall, S.A, a global ph ...

The incidence of acne varies by transgender status, in a multicenter cohort study of transgender individuals starting hormone ...

This can have a huge impact on your circulation, and it can cause symptoms like numbness and tingling in your hands and feet, headache, and vision changes. Even worse, severe cases are associated with ...

"T acne" is a problem for transmasc men, but transfeminine women get it, too.

In A Nutshell Dissolving microneedle patches embedded with microscopic bubbles deliver three acne medications simultaneously, ...

Skorr’s powerful but gentle exfoliating brush effortlessly transformed the texture and tone of my bumpy skin in just one month. Here’s why I vouch for this tool.

The open-label Phase 3 trial evaluated the safety of ASC40 (denifanstat) tablets in patients with moderate to severe acne over a 40-week period. Denifanstat is being developed by Ascletis for acne in ...